Hillstream BioPharma, Inc. Stock Price, News & Analysis

Hillstream BioPharma (Nasdaq: HILS) has announced promising initial results in a study evaluating the synergy between its therapeutic candidate HSB-1216 and Pembrolizumab, an anti-PD-1 antibody, in treating KRAS G12C-mutated non-small cell lung cancer (NSCLC). The study showcases a significant increase in tumor inhibition of Calu-1 cells, indicating a potential new avenue for enhancing treatment efficacy in NSCLC.

Despite advancements in anti-PD-1 therapies, survival rates in NSCLC remain low, suggesting a clear need for novel treatment combinations. HSB-1216 targets ferroptosis, a new anti-cancer mechanism, and is expected to enter clinical trials in 2023.

Hillstream BioPharma (Nasdaq: HILS) announced a preclinical update on its first-in-class dual inhibitor HSB-510, targeting PI3-Kδ and HDAC6, in combination with navitoclax. The findings will be presented at the 2023 AACR Annual Meeting on April 17, 2023, in Orlando. The abstract indicates that HSB-510 significantly inhibits the growth of triple-negative breast cancer (TNBC) cells and MYC levels in preclinical studies. HSB-510 demonstrates favorable pharmacokinetic properties and is expected to advance toward IND-enabling studies in 2023. The company is optimistic about further collaboration with NCATS and advancing its drug candidates.

Hillstream BioPharma (Nasdaq: HILS) announced its upcoming virtual R&D Day on February 14, 2023, highlighting its innovative treatments targeting drug-resistant cancers. The company focuses on ferroptosis, a new mechanism of iron-mediated cell death, and is advancing two key candidates: HSB-1216, which targets cancer stem cells (CSCs), and HSB-1940, an anti-PD-1 Quatrabody™ that aims for improved binding to undruggable epitopes. Notably, Hillstream has secured an exclusive option agreement with Dana-Farber Cancer Institute for developing anti-MUC1-C antibodies, enhancing its therapeutic potential in immuno-oncology.

Hillstream BioPharma (Nasdaq: HILS) has signed an exclusive option agreement with Dana-Farber Cancer Institute to license MUC1-C targeting technology. This partnership aims to develop anti-MUC1-C antibodies that will enhance Hillstream's lead candidate, HSB-1216, which utilizes a Quatramer platform designed to induce ferroptosis in drug-resistant cancers. The MUC1-C protein is significant in various aggressive cancers, including triple-negative breast cancer and small cell lung cancer. Hillstream expects to initiate clinical trials for HSB-1216 in 2023, with ongoing discussions for IND submissions to the FDA.

Hillstream BioPharma, Inc. (Nasdaq: HILS) is set to present at the Virtual Sidoti Micro-Cap Conference on January 18-19, 2023. CEO Randy Milby will speak on January 19 at 10:00 a.m. EST and is available for 1-on-1 meetings with investors. Hillstream is focusing on drug-resistant cancers and is advancing its lead candidate, HSB-1216, which targets ferroptosis—a new anti-cancer mechanism. The company plans to initiate IND discussions with the FDA in the first half of 2023. Hillstream also develops proprietary platforms such as Quatramer™ and Quatrabody™ to enhance drug efficacy and safety.

Hillstream BioPharma (Nasdaq: HILS) announced the development of HSB-1940, a targeted biologic against PD-1, leveraging the long half-life of Quatramers and Picobodies. Collaboration with OmniAb and Minotaur Therapeutics aims to advance this innovative immunotherapy into the rapidly growing field of immuno-oncology. The combination of Quatramers and Picobodies is expected to enhance binding affinity to difficult epitopes. Hillstream's CEO expressed optimism about creating novel therapeutics, positioning the company for significant growth in the market.

Hillstream BioPharma (Nasdaq: HILS) will present at the 2022 RHK Capital Disruptive Growth Conference on December 6, 2022, in New York City. CEO Randy Milby will showcase the company’s innovative cancer treatment focusing on ferroptosis, which induces iron-mediated cell death in resistant cancers. Milby will also hold one-on-one meetings with investors. Hillstream aims to initiate discussions with the FDA on its candidate HSB-1216, which showed efficacy in treating aggressive cancers. For more details, visit www.hillstreambio.com.

Hillstream BioPharma announced the presentation of an abstract on HSB-1216, a novel ferroptosis inducer targeting acute myeloid leukemia (AML), at the 34th EORTC-NCI-AACR Symposium from October 26-28, 2022. HSB-1216 demonstrated significant growth inhibition in AML cell lines, including those resistant to standard therapies. The Quatramer platform enhances its effectiveness by increasing drug uptake in tumors with minimal toxicity. CEO Randy Milby highlighted the unmet need for effective AML treatments and the potential for HSB-1216 in various solid tumors.

Hillstream BioPharma, Inc. (Nasdaq: HILS) announced that CEO Randy Milby will present and hold one-on-one meetings at two upcoming conferences: the Dawson James Securities 7th Annual Small Cap Growth Conference on October 12, 2022, and the ThinkEquity Conference on October 26, 2022. The company focuses on developing therapeutic candidates targeting ferroptosis, an anti-cancer mechanism. Hillstream's leading drug candidate, HSB-1216, showed efficacy in treating severe cancers and aims to begin discussions with the FDA in early 2023.